Jeffrey W. Albers Sells 5,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $102.28, for a total value of $511,400.00. Following the transaction, the director now directly owns 157,557 shares in the company, valued at approximately $16,114,929.96. This represents a 3.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Blueprint Medicines Trading Down 0.9 %

Blueprint Medicines stock opened at $103.95 on Friday. Blueprint Medicines Co. has a 12-month low of $72.24 and a 12-month high of $121.90. The stock has a market capitalization of $6.60 billion, a PE ratio of -49.27 and a beta of 0.61. The firm has a 50 day simple moving average of $93.85 and a 200-day simple moving average of $95.36. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.32 and a quick ratio of 3.27.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The company had revenue of $128.20 million for the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm’s revenue for the quarter was up 126.5% on a year-over-year basis. During the same period last year, the firm earned ($2.20) EPS. As a group, equities research analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on BPMC. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. JPMorgan Chase & Co. began coverage on shares of Blueprint Medicines in a report on Thursday, November 14th. They issued an “overweight” rating and a $126.00 price target for the company. Stephens reiterated an “overweight” rating and set a $140.00 price objective on shares of Blueprint Medicines in a research note on Thursday, January 2nd. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research note on Wednesday, December 11th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a report on Monday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Blueprint Medicines presently has a consensus rating of “Moderate Buy” and an average target price of $122.72.

Institutional Investors Weigh In On Blueprint Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP bought a new stake in shares of Blueprint Medicines in the 3rd quarter worth approximately $32,000. Covestor Ltd grew its position in Blueprint Medicines by 206.7% in the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares during the last quarter. Quantbot Technologies LP bought a new position in shares of Blueprint Medicines in the third quarter valued at $108,000. Values First Advisors Inc. acquired a new stake in shares of Blueprint Medicines during the 3rd quarter valued at $122,000. Finally, CWM LLC boosted its stake in shares of Blueprint Medicines by 69.2% during the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after acquiring an additional 765 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.